Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers. It develops QINPREZO (vosaroxin), an anti-cancer quinolone derivative, or AQD — a class of compounds. The company conducts research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology.